Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr. Tim Sayed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Tim Sayed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ep. 15 - GLP1 Breakthroughs and Real Results

28:23
 
Share
 

Manage episode 497219513 series 3635298
Content provided by Dr. Tim Sayed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Tim Sayed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of The Scalpel’s Edge, Dr. Tim Sayed breaks down compelling new research on GLP1 medications like semaglutide, tirzepatide, and the latest entrant, ecnoglutide. With real-world data from Cleveland Clinic and insights from an international Phase 3 trial, Dr. Sayed explores how these medications are performing outside of clinical trials, what happens after patients stop taking them, and why cost, side effects, and genetic profiles may impact their effectiveness.

As a board-certified plastic surgeon who has personally used these medications, Dr. Sayed shares clinical insight, practical considerations, and where innovation in weight loss treatment is headed next. If you're curious about the future of GLP1s, their metabolic benefits, and what it means for real patients, this one’s for you.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

  continue reading

16 episodes

Artwork
iconShare
 
Manage episode 497219513 series 3635298
Content provided by Dr. Tim Sayed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Tim Sayed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode of The Scalpel’s Edge, Dr. Tim Sayed breaks down compelling new research on GLP1 medications like semaglutide, tirzepatide, and the latest entrant, ecnoglutide. With real-world data from Cleveland Clinic and insights from an international Phase 3 trial, Dr. Sayed explores how these medications are performing outside of clinical trials, what happens after patients stop taking them, and why cost, side effects, and genetic profiles may impact their effectiveness.

As a board-certified plastic surgeon who has personally used these medications, Dr. Sayed shares clinical insight, practical considerations, and where innovation in weight loss treatment is headed next. If you're curious about the future of GLP1s, their metabolic benefits, and what it means for real patients, this one’s for you.

Contact Dr. Tim Sayed:
Phone: (858) 247-2933
Email: [email protected]
Website: timsayedmd.com
Instagram: @timsayedmd
YouTube: @Timsayedmd
Facebook: Tim Sayed MD

  continue reading

16 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play